Objective: To investigate the efficacy of apatinib combined with ticio in the treatment of recurrent and metastatic esophageal cancer and the effect on the score of Quality of Life Questionnaire-Core 30 (QLQ-30). Methods: A total of 103 patients were randomly selected from January 2017 to December 2019 for this study. After screening by inclusion and exclusion criteria, a total of 100 patients with recurrent and metastatic esophageal cancer were enrolled in this study. The patients were divided into a control group (n=50) and a study group (n=50) by average grouping method. The patients were treated with ticio monotherapy and apatinib combined with ticio respectively, and the clinical therapeutic effects of the two groups were compared. Results: The effective rate of short-term treatment in the study group was 72.00%, significantly higher than 46.00% in the control group (P<0.05). The incidence of toxic and side effects in the study group was significantly lower than that in the control group (40.00% vs 60.00%, P<0.05). The total QLQ-30 score and the scores of each item in the study group were higher than those in the control group after the intervention (P<0.05). Conclusion: Apatinib combined with ticio in the treatment of recurrent and metastatic esophageal cancer can rapidly inhibit the rate of angiogenesis in the tumor, have a certain control effect on the development of metastatic esophageal cancer, stabilize the disease development of patients, and improve the prognosis of life quality.